Who is sponsoring NCT07374419?

NCT07374419 is sponsored by Nerviano Medical Sciences (Shanghai) Ltd..

What drugs are being tested in NCT07374419?

Interventions in NCT07374419: atamparib escalation levels, atamparib RP2D.

What condition does NCT07374419 study?

NCT07374419 studies NSCLC Adenocarcinoma, Solid Tumor.

Is NCT07374419 still recruiting?

NCT07374419 is currently not yet recruiting. Last updated 28 January 2026.

Last reviewed 2026-01-28 · How we verify

NCT07374419: PARP7

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atamparib in Patients With Advanced Solid Tumors

Not yet recruiting Phase 1, PHASE2 Last updated 28 January 2026

What this trial tests

Phase 1, PHASE2 trial testing atamparib escalation levels in NSCLC Adenocarcinoma in 178 participants. Not yet recruiting.

Timeline

10 February 2026

Primary endpoint
31 July 2028

31 January 2029

Quick facts

Lead sponsor	Nerviano Medical Sciences (Shanghai) Ltd.
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	178
Start date	10 February 2026
Primary completion	31 July 2028
Estimated completion	31 January 2029
Sites	1 location across China

Drugs / interventions tested

atamparib escalation levels — full drug profile →
atamparib RP2D — full drug profile →

Conditions studied

NSCLC Adenocarcinoma — all drugs for NSCLC Adenocarcinoma →
Solid Tumor — all drugs for Solid Tumor →

Sponsor

Nerviano Medical Sciences (Shanghai) Ltd. — full company profile →

Who can join

18 and older, any sex, with NSCLC Adenocarcinoma or Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for NSCLC Adenocarcinoma

Currently open trials in the same condition.

NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
NCT03252938 — Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07374419 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nerviano Medical Sciences (Shanghai) Ltd.
Last refreshed: 28 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07374419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing